Wednesday, September 9, 2026
← Back to archivePolicy
Policy•Fierce Biotech•Sep 8, 2026
FDA approves AstraZeneca’s Etcamah, opening ctDNA-guided treatment paradigm in breast cancer
background ▾
- •FDA approved Etcamah despite overwhelming rejection by its own advisory committee and initial regulatory skepticism, signaling formal endorsement of liquid biopsy-guided intervention as a valid clinical paradigm in oncology before radiographic progression.
- •The approval expands the addressable market significantly—AZ estimates ~37,000 HR+ metastatic breast cancer patients in the U.S. annually—and establishes a new standard-of-care approach that could reshape sequencing in HR+/HER2- disease.
- •Watch for Serena-4 first-line trial readout this year; failure to confirm benefit would jeopardize the accelerated approval label. Also monitor adoption rates and whether other SERDs pursue similar ctDNA-guided strategies, and track real-world ESR1 mutation prevalence and detection timing.
AstraZenecacamizestrant (Etcamah)
→ Read original articlePolicy•STAT News•Sep 9, 2026
Opinion: Autonomous AI will beat AI-assisted physicians at some medical tasks by 2030
background ▾
- •Autonomous AI reportedly outperforms both unaided physicians and AI-assisted physicians at five core medical tasks based on recent peer-reviewed comparisons; autonomous AI beat physicians with AI support at diagnosis by 21.3 percentage points in cited studies.
- •Authors project real-world implementation readiness for autonomous AI superiority in some or all five cognitive medical tasks by 2030, contingent on regulatory approval and overcoming physician adoption resistance.
- •Watch for regulatory pathways and real-world trial data on autonomous AI in clinical decision-making; physician and institutional pushback may delay implementation despite technical capability.
Policy•STAT News•Sep 9, 2026
Opinion: AMA CEO: AI won’t replace doctors — it will work alongside them
background ▾
- •AMA leadership is publicly staking a position that AI augments rather than replaces physician practice, framing the debate around responsibility and the non-automatable aspects of medicine.
- •The opinion highlights an unresolved liability and accountability gap: as AI assumes clinical roles, questions remain about who bears responsibility for algorithmic errors and misdiagnoses.
- •Watch for how regulators and payers respond to these responsibility questions as autonomous AI systems move into clinical deployment and reimbursement decisions.
Policy•KFF•Sep 8, 2026
Mapping the Global Health Landscape: Analysis of Fourteen International Organizations
background ▾
- •This is a descriptive analytical tool rather than industry-moving news—it documents organizational landscape without performance assessment or regulatory/commercial implications for pharma companies
Policy•Endpoints News•Sep 8, 2026
Current heads of CBER, CDER snag permanent jobs
background ▾
- •CDER and CBER leadership positions have been made permanent, ensuring regulatory continuity during FDA commissioner transition
- •This stabilizes the review process for drug and biologic applications during a period of potential policy uncertainty
Market Access
Market Access•Fierce Biotech•Sep 8, 2026
Boston Scientific cyberattack likely to have ‘material impact’ on financial results
background ▾
- •Boston Scientific cannot meet 2026 Q3 and full-year financial guidance due to cyberattack-driven operational disruption with material revenue impact
- •Company expects partial revenue recovery but acknowledges full impact unknown; stock fell 4% on the disclosure
- •Monitor Q3 2026 earnings release and updates on supply chain recovery timeline and actual revenue loss quantification
Boston Scientific
→ Read original articleMarket Access•Endpoints News•Sep 8, 2026
Expanding its biopharma plans, Anthropic looks for a life sciences dealmaker
background ▾
- •Anthropic is actively recruiting dealmaking talent in biopharma, indicating serious intent to enter life sciences partnerships or M&A
Anthropic
→ Read original articleMarket Access•Endpoints News•Sep 8, 2026
Sandoz unveils plan for biosimilar expansion and new $300M factory in Slovenia
background ▾
- •Sandoz plans to expand its biosimilar pipeline by more than 700% with new $300M manufacturing capacity in Slovenia
- •This represents a significant strategic bet by the newly independent company to compete in the growing biosimilar market
SandozNovartis
→ Read original articleMarket Access•Fierce Biotech•Sep 8, 2026
Building the Data Foundation for AI-Driven Clinical Development
background ▾
- •H1 and Novo Nordisk are building a unified clinical data and decision platform that preserves decision continuity across study design, country allocation, site selection, and execution—moving beyond isolated tools to a connected ecosystem
- •Novo Nordisk's StudyHub has already achieved enterprise-scale deployment with 1,500+ regular users, providing a proven foundation for AI integration
- •The initiative highlights a critical gap in clinical development: abundant data exists but remains siloed across teams, limiting AI's ability to deliver context-driven insights rather than fragmented recommendations
H1Novo Nordisk
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Sep 8, 2026
Pharvaris' latest phase 3 win builds case for HAE drug with FDA verdict pending
background ▾
- •CHAPTER-3 Phase 3 trial met primary endpoint with 83% reduction in monthly HAE attacks (87% in HAE type 1/2 subgroup), supporting both on-demand and prophylactic development pathways
- •Deucrictibant's dual formulation strategy—immediate-release (under FDA review, decision April 2027) and extended-release prophylactic (NDA planned H1 2027)—positions it as potential first oral therapy combining on-demand efficacy with long-term prevention
- •Monitor FDA approval decision (April 2027) and competitive dynamics: KalVista's Ekterly is established competition, while Intellia's lonvoguran ziclumeran gene-editing approach represents emerging disruptive threat to oral therapies
PharvarisKalVista PharmaceuticalsIntellia TherapeuticsdeucrictibantEkterlylonvoguran ziclumeran
→ Read original articleClinical Trials•Fierce Biotech•Sep 8, 2026
Bristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpoint
background ▾
- •Quintessential trial hit primary ORR endpoint and key secondary complete response endpoint, supporting arlo-cel's potential in the competitive GPRC5D CAR-T space dominated by J&J's Talvey (72% ORR in Monumental-1)
- •One-time CAR-T therapy may offer superior safety/tolerability profile over continuous bispecific antibody treatment, a potentially significant differentiator in patient-centered outcomes
- •Watch for full trial data presentation and FDA's approval decision given recent guidance requiring superiority; competitive dynamics intensifying with AbbVie, AstraZeneca, Legend, and Sanofi also pursuing GPRC5D programs
Bristol Myers SquibbJohnson & JohnsonAbbViearlocabtagene autoleucelarlo-celTalvey
→ Read original articleClinical Trials•Fierce Biotech•Sep 8, 2026
Inhibrx CEO says progression-free survival data leave ‘no question’ about OX40 agonist’s durability
background ▾
- •INBRX-106 + Keytruda achieved 9.6-month median PFS versus 4.9 months for Keytruda monotherapy in HNSCC, with 48.3% ORR versus 26.5%, meeting the primary endpoint and demonstrating durable benefit maturation
- •HPV+ oropharyngeal cancer subgroup showed 80% ORR with unreached median PFS, substantially outperforming the broader population and providing a potential accelerated approval pathway
- •If FDA grants breakthrough designation on phase 2 data, phase 3 HexAgon trial expansion could serve as the confirmatory study; watch for FDA pre-phase 3 meeting outcome and HPV+ cohort expansion readout
Inhibrx BiosciencesMerck & Co.AmgenINBRX-106Keytrudapembrolizumab
→ Read original articleClinical Trials•Fierce Biotech•Sep 8, 2026
AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD
background ▾
- •Tozorakimab achieved 29-34% exacerbation reduction in primary population (former smokers) and 29-30% in overall population, with consistent benefits across prespecified subgroups and eosinophil counts
- •AstraZeneca's dual-pathway mechanism (ST2 + RAGE inhibition) appears clinically differentiated versus competitor ST2-only molecules that failed to achieve two positive pivotal COPD trials
- •FDA priority review granted; regulatory decision expected within 6 months; commercial launch and uptake against Dupixent and other IL-33 candidates will be critical to monitor
AstraZenecaSanofiRegenerontozorakimabDupixent (dupilumab)
→ Read original articleClinical Trials•Fierce Biotech•Sep 8, 2026
Spyre's 3-pronged IBD strategy on track as IL-23 antibody rounds off trio of phase 2 wins
background ▾
- •SPY003 met primary endpoint (10-point RHI reduction by Week 12) and key secondary endpoints (20% clinical remission, 30% endoscopic improvement) in 44-patient phase 2 UC induction study, completing Spyre's trifecta of positive phase 2 readouts in five months
- •Spyre's strategy to test three distinct mechanisms (α4β7, TL1A, IL-23) in a unified Skyline platform positions potential combination therapies against crowded market including Entyvio, Skyrizi, Rinvoq, and Tremfya; Part B will evaluate dose levels and combinations with 2027 data expected
- •Watch Part B Skyline combination results and competitive positioning versus Merck's tulisokibart (anti-TL1A, phase 3 positive); Spyre's claimed 3× longer half-life advantage for SPY001 vs. Entyvio and multi-mechanism approach warrant close monitoring as IBD space consolidates around biologics
Spyre TherapeuticsTakedaAbbVieSPY003SPY001SPY002
→ Read original article